Welcome to our dedicated page for INVVY news (Ticker: INVVY), a resource for investors and traders seeking the latest updates and insights on INVVY stock.
About Indivior PLC
Indivior PLC (symbol: INVVY) is a globally recognized pharmaceutical company dedicated to transforming the treatment landscape for substance use disorders (SUD) and serious mental health conditions. Headquartered in Richmond, Virginia, USA, Indivior operates across 37 countries and employs over 1,000 professionals. The company's mission centers on providing evidence-based treatment options to address the chronic and co-occurring conditions of SUD, aiming to shift the global perception of addiction from a crisis to a treatable chronic disease.
Core Business and Expertise
Indivior specializes in developing and commercializing innovative medications that target opioid addiction, overdose reversal, and other substance-related disorders. Its portfolio includes a range of products designed to address both acute and long-term challenges associated with SUD. A notable product is OPVEE®, an intranasal nalmefene spray approved for the emergency treatment of opioid overdoses. This product exemplifies Indivior's focus on rapid-acting solutions to combat the opioid crisis, particularly in cases involving synthetic opioids like fentanyl. Additionally, the company is expanding its pipeline to include treatments for alcohol use disorder and cannabis use disorder, further broadening its impact in the addiction treatment space.
Market Position and Competitive Landscape
Operating within the pharmaceutical industry, Indivior occupies a specialized niche focused on addiction and mental health treatments. The company distinguishes itself through its commitment to evidence-based solutions and its ability to address both the physical and psychological dimensions of addiction. In a competitive landscape that includes other pharmaceutical firms targeting SUD, Indivior's emphasis on innovation, regulatory compliance, and global reach positions it as a key player. Its products are tailored to meet the urgent needs of healthcare providers and patients, offering life-saving interventions and long-term management options.
Revenue Model and Operations
Indivior's revenue is primarily derived from the sale of its proprietary medications. The company operates in a highly regulated environment, ensuring that its products meet stringent safety and efficacy standards. Its global operations allow it to address diverse market needs, although it faces challenges such as navigating country-specific regulations and addressing the stigma associated with addiction treatment. Despite these hurdles, Indivior's focus on unmet medical needs and its robust product pipeline underscore its resilience and adaptability in a dynamic industry.
Significance in the Industry
Indivior plays a critical role in addressing the global opioid crisis, a public health emergency that claims thousands of lives annually. By offering rapid-acting and effective treatments like OPVEE, the company contributes to reducing opioid-related fatalities and improving patient outcomes. Its comprehensive approach to SUD, which includes addressing co-occurring mental health disorders, reflects a deep understanding of the complexities involved in addiction treatment. This positions Indivior as a trusted partner for healthcare providers and a vital resource for patients worldwide.
Commitment to Innovation
Indivior's dedication to research and development is evident in its expanding pipeline of product candidates. By leveraging clinical insights and pharmacological expertise, the company aims to develop treatments that not only address current challenges but also anticipate future needs in the addiction treatment landscape. This commitment to innovation ensures that Indivior remains at the forefront of its industry, continually enhancing its impact on public health.
Indivior PLC has enrolled the first patient in a Phase 2b study for AEF0117, targeting cannabis use disorder (CUD). This follows a collaboration with Aelis Farma to develop this first-in-class treatment. The trial aims to evaluate the efficacy, safety, and tolerability of AEF0117, building on promising Phase 2a results. Approximately 14.2 million people in the U.S. reportedly had CUD in the past year, highlighting the treatment's potential public health impact. Successful completion may lead AEF0117 to Phase 3 trials, supported by a $7.8 million NIH grant.
Indivior PLC (LON: INDV) released its financial results for Q1 2022, ending March 31, 2022. Although the specific figures were not disclosed in the PR, the company emphasizes its commitment to developing medicines for substance use disorders and serious mental illnesses. Indivior's global portfolio targets opioid use disorder and aims to address associated chronic conditions. The company continues to operate globally, employing over 900 individuals, and is focused on expanding its product pipeline for better patient access.
Indivior announces its commitment to enhance access to medications addressing opioid use disorder, amid a nationwide spike in fentanyl-related overdoses. The CDC reports over 105,000 overdose deaths in the year ending October 2021, with a significant proportion linked to synthetic opioids. Indivior's CEO emphasizes the urgent need for evidence-based treatment solutions, particularly in underserved communities facing barriers to care. The company aims to address racial and ethnic disparities in treatment and emphasizes the importance of access for individuals involved in the criminal justice system.
Indivior PLC has published modeling data in JCI Insight exploring how buprenorphine can mitigate fentanyl-induced respiratory depression. The study indicates that buprenorphine plasma concentrations of 2 ng/mL and above may protect chronic opioid users from respiratory depression triggered by fentanyl. Although the study was conducted in a controlled environment with a limited number of participants, it suggests that buprenorphine's ability to occupy mu-opioid receptors can prevent respiratory issues when combined with fentanyl. Further research in real-world settings is warranted.
Indivior PLC announced on March 31, 2022, the initiation of formal consultations with shareholders regarding a potential additional listing on a major US stock exchange. The Board believes that this move could enhance the company’s profile in its largest market, where approximately 80% of its net revenue is generated. Indivior aims to attract a broader base of biopharma investors and research analysts, with a potential resolution planned for September 2022. The earliest implementation could occur in Spring 2023.
Indivior PLC (LON: INDV) reported its financial results for the fiscal year ending December 31, 2021, showcasing its commitment to addressing substance use disorders and mental illnesses. The company aims to enhance access to evidence-based treatments globally. Indivior's product pipeline focuses on opioid use disorder treatments and related chronic conditions. The earnings release, investor presentation, and additional materials are available online, with a webcast presentation scheduled for today at 8:00 AM US EST.
Indivior announced the publication of a clinical pharmacology study in PLOS ONE, demonstrating that buprenorphine can significantly reduce respiratory depression caused by fentanyl in both healthy volunteers and opioid-tolerant patients. Results showed that the decrease in minute ventilation was reduced by nearly 60% with buprenorphine compared to a placebo. The FDA recently updated the label for SUBLOCADE to include data from this study, affirming its efficacy in treating opioid use disorder amidst the ongoing opioid crisis, which saw over 101,000 overdose deaths in the U.S. within a year.
Indivior PLC (LON: INDV) presented a study at the NCCHC 2021 conference focusing on opioid use disorder (OUD) treatment barriers in the criminal justice system. The mixed methods study included literature reviews and interviews with addiction specialists. Key findings revealed that nearly 20% of state prison inmates regularly use opioids, highlighting stigma and resource shortages that restrict treatment access. The study emphasized a preference for the injectable version of buprenorphine, while patient concerns about withdrawal were notable. Data showed similar emergency department visit rates for criminal justice-involved and non-involved individuals receiving treatment.
Indivior PLC announced new findings at the CSAM-SMCA 2021 Scientific Conference held virtually from October 21-23, 2021. The data presented focuses on addressing challenges in treating opioid use disorder (OUD). Chief Scientific Officer Christian Heidbreder emphasized the importance of science-based treatment options. Key abstracts include studies on heroin users' management during COVID-19 and the benefits of buprenorphine injections. Indivior is dedicated to transforming addiction treatment and enhancing patient care worldwide.
Indivior PLC presented new research at the CPDD 83rd Annual Scientific Virtual Meeting, highlighting critical issues in opioid use disorder during the COVID-19 pandemic. The data covers topics like the impact of COVID-19 on recovery rates, comparative studies of SUBLOCADE maintenance doses, and patient outcomes in diverse healthcare settings. Key findings include a 26% increase in recovery difficulty due to COVID-19 and a higher retention rate among patients using 300 mg SUBLOCADE doses. Furthermore, the study revealed an alarming rise in buprenorphine-involved mortality rates from 0.006 in 2010 to 0.068 in 2017, emphasizing the ongoing opioid crisis.
FAQ
What is the market cap of INVVY (INVVY)?
What does Indivior PLC specialize in?
How does Indivior generate revenue?
What is OPVEE, and how is it used?
What makes Indivior unique in its industry?
What challenges does Indivior face in its market?
What is Indivior's approach to addressing the opioid crisis?
Does Indivior operate globally?
What other conditions does Indivior aim to treat beyond opioid addiction?
Who are Indivior's primary customers?
What role does evidence-based medicine play in Indivior's operations?
